The E. W. Scripps Company (NYSE:SSP) shares decreased -1.95% in last trading session and ended the day at $17.56. SSP Gross Margin is 83.40% and its has a return on assets of -3.30%. The E. W. Scripps Company (NYSE:SSP) quarterly performance is -16.26%.
Rich Boehne, chairman, president and chief executive officer of The E.W. Scripps Company (NYSE:SSP) discussed the company’s business strategies at NobleCon12 – the Noble Financial Capital Markets’ 12th Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, Jan. 19.
Equity Commonwealth (NYSE:EQC) ended the last trading day at $26.18. Company weekly volatility is calculated as 2.53% and price to cash ratio as 2.01. Equity Commonwealth (NYSE:EQC) showed a weekly performance of -3.75%.
Equity Commonwealth (NYSE: EQC) announced that the company will release its fourth quarter and full year 2015 operating results on Wednesday, February 17, 2016, after market close. A conference call to discuss those results will be held on Thursday, February 18, 2016, at 9:00 am Central Time.
On 20 January, ArQule Inc. (NASDAQ:ARQL) shares moved up 2.23% and was closed at $1.83. ARQL EPS growth in last 5 year was 14.70%. ArQule Inc. (NASDAQ:ARQL) year to date (YTD) performance is -15.67%.
RBC Capital upgraded shares of ArQule, Inc. (NASDAQ:ARQL) to a buy rating in a research note published on Sunday, MarketBeat Ratings reports.
Spark Therapeutics, Inc. (NASDAQ:ONCE) shares moved up 13.32% in last trading session and ended the day at $31.13. ONCE has a return on assets of -25.30%. Spark Therapeutics, Inc. (NASDAQ:ONCE) quarterly performance is -41.91%.
Spark Therapeutics Inc. (NASDAQ:ONCE) outlined a comprehensive three-year vision for expanding the company’s portfolio through 2018 and launching its first commercial product in 2017, during a presentation this afternoon at the J.P. Morgan 34th Annual Healthcare Conference in San Francisco. Spark Co-founder and Chief Executive Officer, Jeffrey D. Marrazzo, outlined plans for advancing 10 total programs across three therapeutic franchises by 2018, including one commercially approved therapy, two product candidates in pivotal-stage trials and at least seven additional programs in clinical proof-of-concept trials. The company’s 2018 vision for its portfolio is fully funded with existing financial resources, Marrazzo said.
Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) caters to the Healthcare space. Its weekly performance is -14.77%. On the last day of trading company shares ended up at $1.27. Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) distance from 50-day simple moving average (SMA50) is -8.09%.
On 11 January, Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) announced that CPX-351 (also known as VYXEOS™) has been selected for participation in a Cardiff University-sponsored clinical trial in adult patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
Leave a Reply